Funding for this research was provided by:
Text and Data Mining valid from 2019-02-04
Received: 27 July 2018
Accepted: 7 January 2019
First Online: 4 February 2019
Ethics approval and consent to participate
: The QUANARIE trial was reviewed and approved by the local ethics committee (Comité de protection des personnes EST-II, Besançon) on the 24th October 2016. Approval from the National Authority for the Safety of Medicines and Health Products (Agence nationale de sécurité du medicament et des produits de santé (ANSM)) was obtained on the 16th December 2016. The QUANARIE study is registered with the Clinical Trials Registry (ClinicalTrials.org; Identifier: NCT03062410).All participants will provide written informed consent in accordance with the Declaration of Helsinki.
: All authors have read the manuscript and given consent for its publication.
: A.T.-V. and G.M. received honoraria from Novartis, Pfizer, Roche, BMS, and Ipsen. A.A. received travel fees from Novartis and Roche. The other authors have stated that they have no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.